Topics

Pfizer to Develop Akcea/Ionis Antisense Candidate for Up to $1.5B

10:24 EDT 7 Oct 2019 | Genetic Engineering News

Pfizer has licensed exclusive global rights to Akcea Therapeutics’ Phase II cardiovascular and metabolic disease candidate AKCEA-ANGPTL3-LRx, through an agreement that could generate up to $1.5 billion-plus for Akcea and its corporate parent Ionis Pharmaceuticals.

The post Pfizer to Develop Akcea/Ionis Antisense Candidate for Up to $1.5B appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: Pfizer to Develop Akcea/Ionis Antisense Candidate for Up to $1.5B

NEXT ARTICLE

More From BioPortfolio on "Pfizer to Develop Akcea/Ionis Antisense Candidate for Up to $1.5B"

Quick Search

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...